| Literature DB >> 30510633 |
Traian Dumitrascu1, Mihai Eftimie2, Andra Aiordachioae2, Cezar Stroescu2, Simona Dima2, Mihnea Ionescu2, Irinel Popescu2.
Abstract
AIM: To identify risk factors for clinically relevant complications after spleen-preserving distal pancreatectomy (SPDP). No previous studies explored potential predictors of morbidity after SPDP.Entities:
Keywords: Body mass index; Male gender; Morbidity; Spleen-preserving distal pancreatectomy
Year: 2018 PMID: 30510633 PMCID: PMC6259023 DOI: 10.4240/wjgs.v10.i8.84
Source DB: PubMed Journal: World J Gastrointest Surg
Demographic, clinical, bioumoral, intraoperative and pathology data of 41 patients with spleen-preserving distal pancreatectomy: A comparative analysis between patients with and without clinically relevant postoperative complications
| Male gender | 12 (29.3%) | 7 (21.2%) | 5 (62.5%) | 0.03 |
| Age, yr | 41 (18–76) | 39 (18–76) | 51 (34–66) | 0.067 |
| Charlson comorbidity index | 0 (0–4) | 0 (0–4) | 1.5 (0–3) | 0.157 |
| Body mass index, kg/m | 25 (19–42) | 24 (19–37) | 34.5 (24–42) | 0.002 |
| Overweight and obesity | 22 (53.6%) | 15 (45.4%) | 7 (87.5%) | 0.049 |
| Overweight | 8 (19.5%) | 7 (21.2%) | 1 (12.5%) | 1 |
| Obesity | 14 (34.1%) | 8 (24.2%) | 6 (75%) | 0.012 |
| Diabetes mellitus | 1 (2.4%) | 0 | 1 (12.5%) | 0.195 |
| Chronic pancreatitis | 6 (14.6%) | 5 (15.1%) | 1 (12.5%) | 1 |
| Preoperative leucocytes number | 7700 (4900-15300) | 7700 (4900–15300) | 7300 (5200–9200) | 0.961 |
| Preoperative neutrophil number | 4900 (2800–13200) | 4900 (2800–13200) | 4050 (3500–6400) | 0.759 |
| Preoperative lymphocyte number | 1800 (1000–3300) | 1600 (1000–3300) | 2200 (1100–2900) | 0.291 |
| Preoperative neutrophil-to-lymphocyte ratio | 2.9 (1.2–8.4) | 2.9 (1.2–8.4) | 2.2 (1.6–5.8) | 0.137 |
| Preoperative platelet number | 262500 (161000–464000) | 264000 (161000–410000) | 258000 (170000–464000) | 0.735 |
| Preoperative platelet-to-lymphocyte ratio | 134 (55.4–372.7) | 134 (55.4–372.7) | 141.9 (85–372.7) | 0.550 |
| ASA score 3 | 6 (14.6%) | 4 (12.1%) | 2 (25%) | 0.577 |
| Minimally invasive approach | 6 (14.6%) | 4 (12.1%) | 2 (25%) | 0.577 |
| Soft pancreas texture | 35 (85.3%) | 28 (84.8%) | 7 (87.5%) | 1 |
| Associated procedures | 5 (12.2%) | 4 (12.1%) | 1 (12.5%) | 1 |
| Operative time, min | 150 (70–330) | 150 (70–320) | 185 (120–330) | 0.067 |
| Estimated blood loss, mL | 150 (50–600) | 150 (50–600) | 175 (50–300) | 0.550 |
| Intraoperative blood transfusions | 1 (2.4%) | 1 (3%) | 0 | 1 |
| Tumor diameter, cm | 3.5 (0.4–14) | 3 (0.4–14) | 2.75 (0.4–3.5) | 0.060 |
| Length of resected pancreas, cm | 9 (6–12) | 9 (6–12) | 8.5 (8–12) | 0.784 |
| Malignant pathology | 4 (2.4%) | 3(9.1%) | 1 (12.5%) | 1 |
| Neuroendocrine pathology | 18 | 11 | 7 | 0.013 |
Fisher’s exact test (two-tailed);
Mann-Whitney test (two-tailed);
Assessed no more than one week prior to surgery. ASA: American Society of Anesthesiologists.